Skip to main content
Erschienen in: The European Journal of Health Economics 5/2015

01.06.2015 | Editorial

Is personalized medicine a panacea for health management? Some thoughts on its desirability

verfasst von: Fernando Antoñanzas, Carmelo A. Juárez-Castelló, Roberto Rodríguez-Ibeas

Erschienen in: The European Journal of Health Economics | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Excerpt

During the last decade we have witnessed a change in health care management. Predictive, personalized [1], individualized [2] or stratified [3] medicine are some of the terms that have been coined to describe a new approach to dealing with disease. In essence, the new paradigm is based on matching patients with the best treatments available according to each patient’s characteristics. Patients are classified through new tests, mainly genetic in nature, the growing proliferation of which is behind the extensive application of this new approach to managing disease. In parallel, new therapies, many based on new mechanisms of action and biological agents, allow ever narrower targets within the cell to be addressed. This combination of new diagnostic techniques and targeted therapies has improved the perspectives of managing some difficult conditions, such as some types of cancer, by controlling the progression of a disease and maintaining it rather as a chronic condition, even achieving a cure in some cases. This new paradigm is raising expectations for both patients and physicians. Health care systems are transforming the management of some diseases and re-writing treatment guidelines to incorporate the advantages of newly available therapies and approaches. However, notwithstanding the rapid development of these changes, there are some issues that should also be taken into account. Here, we highlight some elements that are frequently overlooked or taken for granted. …
Literatur
1.
Zurück zum Zitat Rogowski, W., Payne, K., Schnell-Inderst, P., Manca, A., Rochau, U., Jahn, B., Alagoz, O., Leidl, R., Siebert, U.: Concepts of ‘‘Personalization’’ in personalized medicine: implications for economic evaluation. PharmacoEconomics (2014). doi:10.1007/s40273-014-0211-5 PubMed Rogowski, W., Payne, K., Schnell-Inderst, P., Manca, A., Rochau, U., Jahn, B., Alagoz, O., Leidl, R., Siebert, U.: Concepts of ‘‘Personalization’’ in personalized medicine: implications for economic evaluation. PharmacoEconomics (2014). doi:10.​1007/​s40273-014-0211-5 PubMed
2.
Zurück zum Zitat Hatz, M.H.M., Schremser, K., Rogowski, W.H.: Is individualized medicine more cost-effective? A systematic review. Pharmaco. Economics 32, 443–455 (2014)CrossRefPubMed Hatz, M.H.M., Schremser, K., Rogowski, W.H.: Is individualized medicine more cost-effective? A systematic review. Pharmaco. Economics 32, 443–455 (2014)CrossRefPubMed
3.
Zurück zum Zitat Trusheim, M.R., Berndt, E.R., Douglas, F.L.: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6, 28793 (2007)CrossRef Trusheim, M.R., Berndt, E.R., Douglas, F.L.: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6, 28793 (2007)CrossRef
4.
Zurück zum Zitat Antoñanzas, F., Rodríguez-Ibeas, R., Hutter, M.F., Lorente, R., Juárez, C., Pinillos, M.: Genetic testing in the European Union: does economic evaluation matter? Eur J Health Econ 12(5), 651–662 (2012)CrossRef Antoñanzas, F., Rodríguez-Ibeas, R., Hutter, M.F., Lorente, R., Juárez, C., Pinillos, M.: Genetic testing in the European Union: does economic evaluation matter? Eur J Health Econ 12(5), 651–662 (2012)CrossRef
5.
Zurück zum Zitat Antoñanzas, F., Juárez-Castelló, C.A., Rodríguez-Ibeas, R.: Some economics on personalized and predictive medicine. Eur J Health Econ (2014). doi:10.1007/s10198-014-0647-8 Antoñanzas, F., Juárez-Castelló, C.A., Rodríguez-Ibeas, R.: Some economics on personalized and predictive medicine. Eur J Health Econ (2014). doi:10.​1007/​s10198-014-0647-8
Metadaten
Titel
Is personalized medicine a panacea for health management? Some thoughts on its desirability
verfasst von
Fernando Antoñanzas
Carmelo A. Juárez-Castelló
Roberto Rodríguez-Ibeas
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 5/2015
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-014-0665-6

Weitere Artikel der Ausgabe 5/2015

The European Journal of Health Economics 5/2015 Zur Ausgabe